BioSpace News Archive

CompuMed, Inc. is pleased to announce fiscal 2022 3rd quarter results.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022.

Veru Inc., a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, announced the granting of inducement awards to five new employees.

Mirum Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 521,739 shares, at a price to the public of $23.00 per share.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three and nine months ended June 30, 2022 and provided an update on its business.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics with the potential to modify the course of Parkinson’s disease (“PD”) and related disorders, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent developments.

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.

Karuna Therapeutics, Inc. announced the closing of its previously announced upsized underwritten public offering of 4,011,628 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 523,255 shares at the public offering price of $215.00 per share.

Arcadia Biosciences, Inc.® announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 4,722,506 shares of its common stock at a purchase price of $1.05876 per share in a registered direct offering priced at-the-market under Nasdaq rules.